A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to obtain safety information on the use of sitagliptin
(JANUVIA®) from endocrinologists, diabetologists, internists, and general practitioners.